CME Group Inc. (CME) — Fair Value Analysis

Base-case fair value (P50): $295.87 · Current price: $236.60 · Verdict: Undervalued

The Verdict on CME

Based on rigorous Monte Carlo simulations, CME Group (CME) appears undervalued. Our analysis indicates a median fair value (P50) of $295.87, representing a substantial +25.1% potential from the current market price of $236.60. This finding suggests that CME's present valuation does not fully capture its intrinsic worth as projected across thousands of forward-looking financial scenarios. For investors evaluating CME, this pronounced disparity between $236.60 and $295.87 signals a compelling entry point according to our models, challenging any presumption that CME might be overvalued.

How CME stacks up against Financial Services

While CME operates within the dynamic Financial Services sector, its operational and financial health is categorized as "average" relative to its peers. Despite this average quality tier, the Monte Carlo simulations consistently point to an +25.1% from $236.60 to the $295.87. This outcome highlights that even a company with an average quality profile, like CME, can present significant undervaluation when its market price, currently $236.60, diverges sharply from its probabilistically derived fair value. The quality tier helps contextualize the risk and opportunity, but does not negate the strong statistical signal of potential upside.

What this means for investors

The clear indication that CME is undervalued, with an +25.1% to a median fair value of $295.87 from its current $236.60, should be a key consideration for investors. Despite an average quality tier, the Monte Carlo analysis suggests considerable room for appreciation. While the full distribution, including bear and bull case scenarios and their respective probabilities, is reserved for subscribers, the P50 fair value of $295.87 stands as a robust anchor. To see the full bear/bull distribution and track CME's fair value as new fundamentals are released, sign up for FairCurve.